Tag: offer

Axitinib, Sorafenib Provide Comparable Survival in mRCC Patients VIENNA—Axitinib therapy is linked with an general survival (OS) related to that of sorafenib therapy as second-line remedy of metastatic renal cell carcinoma (mRCC), according to updated findings presented at the European Society for Medical … Read more on Renal and Urology News Lauded kidney cancer drug…